Category Research

Biosciences

Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis

Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis Predicta Biosciences, a precision oncology company, has officially launched its first Laboratory Developed Test (LDT), GenoPredicta, a cutting-edge diagnostic tool designed for use in both blood and bone marrow…

Read MorePredicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis
Pilatus

Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer

Pilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer Pilatus Biosciences, a biotechnology company dedicated to developing next-generation immunometabolic therapies for cancer, has announced the publication of a pivotal preclinical study in Cancer Discovery, a leading peer-reviewed…

Read MorePilatus Biosciences Unveils Preclinical Data on CD36 Antibody PLT012 for Liver Cancer
LEAP

LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics

LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase digital transformations, has announced a strategic executive appointment that marks…

Read MoreLEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics
Pfizer

Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC

Pfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC Pfizer Inc. (NYSE: PFE) announced today significant findings from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with the standard of care (SOC) Bacillus Calmette-Guérin…

Read MorePfizer’s Sasanlimab Boosts Event-Free Survival in High-Risk NMIBC

UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients

UGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, announced new data supporting its investigational intravesical…

Read MoreUGN-102 Trials Show No Impact on Function, Symptoms, or QoL in LG-IR-NMIBC Patients
CytoAgents

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…

Read MoreCytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research
Debiopharm

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…

Read MoreDebiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research
Novocure

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of…

Read MoreNovocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025